Mechanisms for glyproline protection in hypercholesterolemia

Pathophysiology

Volumn 23, Issue 1, 2016, Pages 27-33

  Myasoedov, Nikolay F ^a   Lyapina, Ludmila A ^b   Grigorjeva, Marina E ^b   Obergan, Tamara Y ^b   Shubina, Tatyana A ^b   Andreeva, Ludmila A ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Russian Federation)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

Glyproline peptides; Hemostasis system; Hypercholesterolemia

Indexed keywords

ANTILIPEMIC AGENT; ARGINYLPROLYLGLYCYLPROLINE; GLYPROLINE PEPTIDE; PROLINE DERIVATIVE; PROLYLGLYCYLPROLINE; PROLYLGLYCYLPROLYLLEUCINE; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; FIBRINOLYSIS; HEMOSTASIS; HYPERCHOLESTEROLEMIA; LIPID DIET; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION INHIBITION;

EID: 84949571212     PISSN: 09284680     EISSN: 1873149X     Source Type: Journal    
DOI: 10.1016/j.pathophys.2015.11.001     Document Type: Article

References (43)

1. Ezhov M.B., Afanasyeva O.I., Kambegova A.A., Afanasyeva M.I., Trukhachova E.P., Naumov V.G., Pokrovskii S.N. The role of the atherosclerosis risk factors in the development of heart ischemia in young men. Ter. Arch. 2009, 5:503-505.
2. Martsevich S.Y. Atherosclerosis. Clinical Importance and the Possibility of Prevention 2005, Servicecom Publishers, Moscow.
3. Ashmarin I.P. Pathological Physiology and Biochemistry 2005, Examen Publishers, Moscow.
4. Xiao C., Hsieh J., Adeli K., Lewis G.F. Gut-liver interaction in triglyceride-rich lipoprotein metabolism. Am. J. Physiol. Endocrinol. Metab. 2011, 301:E429-E446.
5. Barkagan Z.S., Kostyuchenko G.I. Metabolic and inflammatory concept of atherothrombosis and new approaches to the treatment of patients. Bull. Sib. Otd. Ross. Akad. Med. Nauk. 2006, 2:132-138.
6. Bokarev I.N. Hemocoagulation 2011. Thromb. Bleed. Vasc. Pathol. 2012, 12:4-8.
7. Li E.D., Lazebnik L.B., Konopleva G.E., Shukhov V.S., Shukhova A.V. The treatment of hyperlipidemias in an outpatient clinic. Intern. Med. J. 2000, 3:265-268.
8. Ikee R., Hamasaki Y., Oka V., Maesato K., Mano T., Moriya H., Ohtake T., Kobayashi S. Clinical: high-density lipoprotein cholesterol and left ventricular mass index inperitoneal dialysis. Perit. Dial. Int. 2008, 28:611-616.
9. Shlomo M., Polonsky K.S., Larsen P.N., Kronenberg G.M. Williams Textbook of Endocrinology 2011, Saunders, Elsevier, Netherlands. 12th ed.
10. Nishitani S., Takehana K., Fujitani S., Sonaka I. Branched-chain amino acid simprove glucose metabolism in rats with liver cirrhosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288:G1292-G1300.
11. Rajesh T., Jose L., Balaji H., Estela L. Metabolism and bioenergetics: activation ofthe lipid droplet controls the rate of lipolysis of triglycerides in the insect fat body. J. Biol. Chem. 2005, 280:22624-22631.
12. Owens A.P., Wang J.-G., Manly D.A., Daugherty A., Mackman N. Gypercholesterolemia increases microparticle tissue factor and activates coagulation in LDL receptor deficient mice. Circulation 2009, 120:S1025.
13. Egger E., Jean-Paul Shmid J.P., Saner B., von Käner R. Depression and anxiety symptoms affect change in exercise capacity during cardiac rehabilitation. Eur. J. Cardiovasc. Prev. Rehabil. 2008, 15:704-708.
14. Watson T., Arya A., Sulke N., Lip G.Y. Antithrombotic therapy: relationship ofindices of inflmmation and thrombogenesis to arithmia burden in paroxysmal arialfibrillation. Chest 2010, 137:869-876.
15. Harris T.D., Mitchel E.W. Changes in environmentaltemperature influence leptin responsivenessin low- and high-fat-fed mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 293:R106-R115.
16. Mantzoros C., Li T., Manson J., Meigs J., Hu F. Endocrine care: circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J. Clin. Endocrinol. Metab. 2005, 90:4542-4548.
17. Napoli C., Stanley W.C., Ignarro L.J. Nutrition and cardiovascular disease: putting apathogenetic framework into focus. Cardiovasc. Res. 2007, 73:253-256.
18. Brunini T.M.C., Mendes-Ribeiro A.C., Ellory J.C., Mann G.E. Platelet nitric oxidesynthesis in uremia and malnutrition: a role for l-arginine supplementation in vascular protection. Cardiovasc. Res. 2007, 73:359-367.
19. McConnel G.K. Effects of l-arginine supplementation exercise metabolism. Curr. Opin. Clin. Nutr. Metab. Care 2007, 10:46-51.
20. Cojocaru E., Zamfir C., Zamosteanu N., Trandafirescu M., Cotuiu C. The effects of branched chain amino acids on HDL-cholecterol in experimental animals subjected to dietary hypercholesterolemia. Rev. Med. Chir. Soc. Med. Nat. Iasi. 2012, 116:200-206.
21. Perrson L., Borén J., Robertson A., Wallenius V., Hansson G., Pekna M. Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E-/-Low-Density Lipoprotein Receptor-/-Mice. J. Atheroscler. Thromb. Vasc. Biol. 2004, 24:1062-1067.
22. Ashmarin I.P., Kamenskii A.A., Lyapina L.A., Myasoedov N.F., Samonina G.E. Glyprolines as independent regulators and stabilizers of other peptides. Probl. Biol. Med. Pharm. Chem. 2002, 1:24-27.
23. Grigorjeva M.E., Kazancheva M.Kh., Lyapina L.A. Anticoagulant effects of arginine-containing peptide Arg-Pro-Gly-Pro under conditions of immobilization stress. Bull. Exp. Biol. Med. 2013, 6:723-727.
24. Lyapina L.A., Andreeva L.A., Ulyanov A.M., Obergan T.Y., Shubina T.A., Myasoedov N.F., Ashmarin I.P. Anticoagulative and antidiabetogenic effects of the tripeptide Gly-Pro-Arg in the development of experimental insulin-dependent diabetes. Thromb. Hemost. Rheol. 2011, 2:53-58.
25. Samonina G., Lyapina L., Kopylova G., Pastorova V., Bakaeva Z., Jeliaznik N., Zuyikova S., Ashmarin I. Protection of gastric mucosal integrity by gelatin and simple proline-containing peptides. Pathophysiology 2000, 7:69-73.
26. Aronov D., Krasnitskii V., Bubnova M., Ioseliani D., Posdniakov Y., Shchegol'kov A., Efremushkin G., Osipova I., Gulyaeva S., Malchikova N., Kazakevitch E., Lyamina N., Ryamzina I., Mingazetdinova L. The effect of physical exercise on the working ability hemodynamics blood lipids, clinical process and prognosis in patients with heartischemic disease after acute cardial events during complex rehabilitation and secondary prevention at the stage of outpatient care. Cardiology 2009, 3:49-56.
27. Kostapanos M.S., Haralampos J.M., Moses S.E. An overview of the extra-lipid effects of rosuvastatin. J. Cardiovasc. Pharmacol. Ther. 2008, 13:157-174.
28. Lyapina L.A., Grigorjeva M.Y., Obergan T.E., Shubina T.A. Theoretical and Practical Issues in Studying the Functional State of the Antiplatelet System 2012, Advanced Solution Publishers, Moscow.
29. Dolgov V.V., Svirin P.V. Laboratory Diagnostics of Hemostasis Disorders 2005, Russian Academy of Med. Postgraduate Education, Triada Publishers, Moscow.
30. Barkagan Z.S., Momot A.P. Diagnostics and Controlled Therapy of Hemostasis Disorders 2001, Newdiamed Publishers, Moscow.
31. Lyapina L.A., Myasoedov N.F., Grigor'eva M.E., Shubina T.A., Andreeva L.A. The contemporary concept of glyproline peptides in the correction of hemostasis system functioning in the progress of diabetes. Biol. Bull. 2013, 4:386-393.
32. Stief T.W. Inhibition of thrombin in plasms by heparin or arginine. Clin. Appl. Thromb. Hemost. 2007, 13:146-153.
33. Melnichenko G.A., Romantsova T.I. Obesity: Epidemiology, Classification, Pathogenesis, Clinical Symptoms and Diagnostics 2004, MIA Publishers, Moscow.
34. Grigorjeva M.E., Obergan T.Y. Possible mechanisms of the antiplatelet and antithrombocytic action of the glycine-containing peptides Pro-Gly-Arg and Gly-Pro-Arg. Thromb. Bleed. Vasc. Dis. 2008, 6:35-36.
35. Myasoedov N.F., Skvortsova V.I., Nasonov E.L., Zhauravleva E.J., Grivennikov I.A., Arsenyeva E.L., Sukhanov I.I. Investigation of mechanisms of neuroprotective effect of Semax inthe acute period of ischemic stroke. Z. Nevropatol. Psikhiatr. Im. S.S. Korsakova 1999, 5:15-19.
36. Telen M.E. Erythrocyte adhesion receptors: blood group antigens and relatedmolecules. Transfus. Med. Rev. 2005, 19:795-799.
37. Olearczyk I.J., Stephenson A.H., Lonigro A.J., Sprague R.S. NO inhibits signaltransduction pathway for ATP release from erythrocytes via its action on heterotrimeric Gprotein G1. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H748-H754.
38. Khirazova Y.E., Maslova M.V., Sokolova N.A. Excessive body weight and obesity. Prir 2012, 2:11-18.
39. Khavinson V.K., Kuznik B.I., Tarnovskaya S.I., Lin'kova N.S. Epigenetic action of peptide LYS-GLU and ALA-GLU-ASP-GLY on the hemostasis system condition. Thromb. Hemost. Rheol. 2013, 3:26-33.
40. Kuznik B.I., Likhanov I.D., Tsepelev V.P., Sizonenko V.A. Theoretical and Clinicalaspects of Bioregulating Therapy in Surgery and Traumatology 2008, Nauka Publishers, Novosibirsk.
41. Andreeva L.A., Myasoedov N.F., Lyapina L.A., Grigor'eva M.E., Obergan T.Y., Shubina T.A. Effect of the PRO-GLY-PRO peptide on hemostasis andlipid metabolism in rats with hypercholesterolemia. Dokl. Biol. Sci. 2013, 1:333-335.
42. Duttaroy A., Kanakaraj P., Osborn B., Scheider H., Pickeral O., Chen C., Zhang G., Kaithamana S., Singh M., Schulingkamp R., Crossan D., Bock J., Kaufman T., Reavey P., Carey-Barber M., Krishnan S., Garcia A., Murphy K., Siskind J., McLean M., Cheng S., Ruben S., Birse C., Blondel O. Development of a long-acting insulin analog using albumin fusiontechnology. Diabetes 2005, 54:251-258.
43. Rosental J. Vitabolic fate of leucine, a significant sterol precursor in adipose tissueand muscle. Am. J. Physiol. 2008, 225:411-418.